Compare RNP & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNP | DSGN |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.2M | 860.7M |
| IPO Year | N/A | 2021 |
| Metric | RNP | DSGN |
|---|---|---|
| Price | $20.63 | $15.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.25 |
| AVG Volume (30 Days) | 152.4K | ★ 907.2K |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | ★ 7.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.27 | $3.52 |
| 52 Week High | $22.99 | $17.25 |
| Indicator | RNP | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 74.81 |
| Support Level | $20.44 | $9.78 |
| Resistance Level | $20.80 | $17.10 |
| Average True Range (ATR) | 0.32 | 0.96 |
| MACD | 0.04 | 0.40 |
| Stochastic Oscillator | 85.18 | 99.43 |
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances. The Fund seeks to achieve its objectives through a portfolio of income producing common stock issued by REITs and preferred and other debt securities.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.